DNTH
Dianthus Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -22.2% ·
share flow +30.0% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | +12 | 36.60M | $3.56B | +16 | −4 |
| Q1 2026 | 87 | +18 | 31.37M | $2.59B | +21 | −3 |
| Q4 2025 | 69 | +2 | 26.03M | $1.07B | +3 | −1 |
| Q3 2025 | 16 | +2 | 17.27M | $679.58M | +2 | — |
| Q2 2025 | 11 | +1 | 11.18M | $208.23M | +1 | — |
| Q1 2025 | 7 | -2 | 3.50M | $63.53M | — | −2 |
| Q4 2024 | 9 | -1 | 2.27M | $49.52M | +1 | −2 |
| Q3 2024 | 9 | +3 | 1.20M | $32.83M | +4 | −1 |
| Q2 2024 | 6 | — | 1.13M | $29.26M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 1.49M | +668.0% | $26.97M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 759.68K | -7.2% | $13.78M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 517.02K | +6.3% | $9.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 517.02K | +6.3% | $9.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 470.88K | +11.6% | $8.54M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 470.88K | +11.6% | $8.54M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 189.00K | +5.0% | $3.43M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 67.98K | +12.7% | $1.23M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 67.98K | +12.7% | $1.23M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 10.49K | +10.8% | $191,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Millennium Management | $1.97M | was 0.0% |
| Two Sigma Investments | $231,102 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 62.10M shares, $4.94B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.78K sh · $326,554
Director · 737 sh · $79,721
Director · 831 sh · $90,537
Director · 272 sh · $29,909
Director · 470 sh · $52,194
Director · 397 sh · $44,373
Director · 700 sh · $77,987
Director · 70 sh · $7,498
Director · 2.80K sh · $303,464
Director · 1.80K sh · $196,740
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology